PMID: 9558129Apr 29, 1998Paper

A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting

Therapeutic Drug Monitoring
B CharpiatJ Baulieux

Abstract

The availability of personal computer programs to individualize drug regimens has stimulated interest in modeling population pharmacokinetics. This study used the NPEM2 software to determine cyclosporine population pharmacokinetic parameter values and distributions in a first group of 25 recipients of liver transplants during their first postoperative week. On a second group of 25 patients, the authors used these values to evaluate Bayesian predictive performance of cyclosporine blood concentrations with the USC*PACK PC program. During the study period, all the patients have been treated by continuous intravenous infusion. The one-compartment model pharmacokinetic parameter-the slope of volume to body weight (Vs) and the elimination rate constant (Kel) values found (mean values: Vs = 2.177 l/kg, Kel = 0.235 h(-1); median values: Vs = 1.559 l/kg, Kel = 0.163 h(-1); the percent coefficient of variation (Vs = 92%, Kel = 79%) appear reasonable and show the ability of NPEM2 to deal with sparse data. When the predictions were studied with day 1, day 2, or day 3 concentrations, predictive bias was respectively -0.030, -0.013, and 0.013 microg/ml, suggesting a greater clearance of cyclosporine immediately after surgery, the clearance d...Continue Reading

References

Nov 1, 1992·Clinical Pharmacology and Therapeutics·D K TurgeonP B Watkins
Dec 1, 1992·Clinical Pharmacokinetics·W M Awni
Jun 1, 1992·Clinical Pharmacokinetics·A H Thomson, B Whiting
Jan 1, 1991·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·K HoppuE L Hirvisalo
Mar 1, 1991·Therapeutic Drug Monitoring·J Grevel, B D Kahan
Aug 1, 1990·Journal of Pharmacokinetics and Biopharmaceutics·M O Karlsson, A Lindberg-Freijs
Jan 1, 1990·Therapeutic Drug Monitoring·F Serre-DebeauvaisM Gavend
Jun 1, 1988·Journal of Pharmacokinetics and Biopharmaceutics·A MalletF Lokiec
Jan 1, 1988·Therapeutic Drug Monitoring·H ChrystynM D Peake
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Apr 1, 1994·Therapeutic Drug Monitoring·G F CooneyG LiBetti
Jun 1, 1993·Clinical Pharmacokinetics·A Fahr
Oct 1, 1995·Journal of Pharmacokinetics and Biopharmaceutics·W M SallasW T Robinson
Feb 1, 1996·Clinical Pharmacokinetics·S VozehL Aarons
Feb 1, 1996·Clinical Pharmacokinetics·S M Tsunoda, F T Aweeka
Mar 1, 1997·Clinical Pharmacokinetics·R G Morris

❮ Previous
Next ❯

Citations

Sep 7, 2001·Transplantation Proceedings·S A Jensen, K P Dalhoff
Dec 21, 2004·British Journal of Clinical Pharmacology·Hélène BourgoinChantal Le Guellec
Jun 8, 2000·Clinical Pharmacokinetics·R J Dumont, M H Ensom
Jun 19, 2013·The AAPS Journal·Kelong HanRaman Venkataramanan
Dec 13, 2005·Journal of Clinical Pharmacy and Therapeutics·J C LukasA D Gil
Feb 24, 2010·Journal of Clinical Pharmacy and Therapeutics·A B RuzilawatiS H Gan
Jun 9, 2006·Pharmacology & Therapeutics·Satohiro Masuda, Ken-ichi Inui
Jun 23, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M BaraldoM Furlanut
Mar 30, 2005·Therapeutic Drug Monitoring·Sara E RosenbaumFatemeh Akhlaghi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.